Moses H, Martin JB. Academic relationships with industry: a new model for biomedical research. JAMA.2001;285:933-935.
Not Available. National Institutes of Health Extramural Data and Trends. Bethesda, Md: National Institutes of Health; 2000.
Thompson D. Understanding financial conflicts of interest. N Engl J Med.1993;329:573-576.
Levinsky N. Nonfinancial conflicts of interest in research. N Engl J Med.2002;347:759-761.
Korn D. Conflict of interest in biomedical research. JAMA.2000;284:2234-2237.
Kassirer J, Angell M. Financial conflicts of interest in biomedical research. N Engl J Med.1993;329:570-571.
Rennie D. Thyroid storm. JAMA.1997;277:1238-1243.
Bodenheimer T. Uneasy alliance: clinical investigators and the pharmaceutical industry. N Engl J Med.2000;342:1539-1544.
Wilson D, Heath D. Uninformed consent. The Seattle Times.March 11-14, 2001:1-14.
Hilts PJ. Company tried to block report that its HIV vaccine failed. New York Times.September 1, 2000:26.
Gillis J. A hospital's conflict of interest: patients weren't told of stake in
cancer drug. Washington Post.June 30, 2002:A1.
Weiss R, Nelson D. Teen dies undergoing experimental gene therapy. Washington Post.September 29, 1999:A1.
Cohen JJ. Trust us to make a difference: ensuring public confidence in the integrity
of clinical research. Acad Med.2001;76:209-214.
Shalala D. Protecting research subjects: what must be done. N Engl J Med.2000;343:808-810.
Blumenstyk G. Association announces guidelines on conflicts of interest in research
involving people. Chronicle of Higher Education.December 18, 2001.
Task Force on Financial Conflicts of Interest in Clinical Research. Protecting Subjects, Preserving Trust, Promoting
Progress: Policy and Guidelines for the Oversight of Individual Financial
Interests in Human Subjects Research. Washington, DC: Association of American Medical Colleges; 2001.
Bero L, Jadad A. How consumers and policymakers can use systematic reviews for decision
making. Ann Intern Med.1997;127:37-42.
Slavin R. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol.1995;48:9-18.
Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med.1997;126:376-380.
Not Available. The Bayh-Dole Act of 1980, 35 USC §200-212 (2000).
Mulrow C, Langhorne P, Grimshaw J. Integrating heterogeneous pieces of evidence in systematic reviews. Ann Intern Med.1997;127:989-995.
Eddy D. Comparing benefits and harms: the balance sheet. JAMA.1990;263:2493-2505.
Gart J. The comparison of proportions: a review of significance tests, confidence
intervals and adjustments for stratification. Rev Int Statist Inst.1971;39:148-169.
Breslow N, Day N. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1987.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies
of disease. J Natl Cancer Inst.1959;22:719-748.
Robins J, Breslow N, Greenland S. Estimators of the Mantel-Haenszel variance consistent in both sparse
data and large-strata limiting models. Biometrics.1986;42:311-323.
Blumenthal D, Campbell EG, Causino N, Louis KS. Participation of life-science faculty in research relationships with
industry. N Engl J Med.1996;335:1734-1739.
Krimsky S, Ennis JG. Academic-corporate ties in biotechnology: a quantitative study. Sci Technol Human Values.1991;16:275-287.
Krimsky S, Rothenberg LS, Stott P, Kyle G. Scientific journals and their authors' financial interests: a pilot
study. Psychother Psychosom.1998;67:194-201.
Blumenthal D, Gluck M, Louis KS, Wise D. Industrial support of university research in biotechnology. Science.1986;231:242-246.
Blumenthal D, Causino N, Campbell E, Louis KS. Relationships between academic institutions and industry in the life
sciences: an industry survey. N Engl J Med.1996;334:368-373.
Pressman L. AUTM Licensing Survey, FY 1999: Survey Summary. Northbrook, Ill: Association of University Technology Managers; 2000.
Blumenthal D, Gluck M, Louis KS.
et al. University-industry research relationships in biotechnology: implications
for the university. Science.1986;232:1361-1366.
Blumenthal D, Causino N, Campbell EG. Academic-industry research relationships in genetics: a field apart. Nat Genet.1997;16:104-108.
Campbell EG, Louis KS, Blumenthal D. Looking a gift horse in the mouth: corporate gifts supporting life
sciences research. JAMA.1998;279:995-999.
Boyd EA, Bero LA. Assessing faculty financial relationships with industry. JAMA.2000;284:2209-2214.
Asch D, Jedrziewski M, Christakis N. Response rates to mail surveys published in medical journals. J Clin Epidemiol.1997;50:1129-1136.
Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med.1986;1:155-158.
Yaphe J, Edman R, Knishkowy B, Herman J. The association between funding by commercial interests and study outcome
in randomized controlled drug trials. Fam Pract.2001;18:565-568.
Djulbegovic B, Lacevic M, Cantor A.
et al. The uncertainty principle and industry-sponsored research. Lancet.2000;356:635-638.
Cho MK, Bero LA. The quality of drug studies published in symposium proceedings. Ann Intern Med.1996;124:485-489.
Turner C, Spilich GJ. Research into smoking or nicotine and human cognitive performance:
does the source of funding make a difference? Addiction.1997;92:1423-1426.
Friedberg M, Saffran B, Stinson TJ.
et al. Evaluation of conflict of interest in economic analyses of new drugs
used in oncology. JAMA.1999;282:1453-1457.
Swaen G, Meijers J. Influence of design characteristics on the outcome of retrospective
cohort studies. Br J Ind Med.1988;45:624-629.
Rochon PA, Gurwitz JH, Simms RW.
et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory
drugs in the treatment of arthritis. Arch Intern Med.1994;154:157-163.
Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med.1998;338:101-106.
Barnes DE, Bero LA. Why review articles on the health effects of passive smoking reach
different conclusions. JAMA.1998;279:1566-1570.
Kjaergard L, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological
study of randomised clinical trials published in the BMJ. BMJ.2002;325:249-253.
Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents
encountered during meta-analysis. JAMA.1999;282:1752-1759.
Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in hepatology: predictors of quality. Hepatology.1999;30:1134-1138.
Anderson JJ, Felson DT, Meenan RF. Secular changes in published clinical trials of second-line agents
in rheumatoid arthritis. Arthritis Rheum.1991;34:1304-1309.
Knox K, Adams J, Djulbegovic B.
et al. Reporting and dissemination of industry versus non-profit sponsored
economic analyses of six novel drugs used in oncology. Ann Oncol.2000;11:1591-1595.
Rochon PA, Gurwitz JH, Cheung CM.
et al. Evaluating the quality of articles published in journal supplements
compared with the quality of those published in the parent journal. JAMA.1994;272:108-113.
Bero LA, Galbraith BA, Rennie D. The publication of sponsored symposiums in medical journals. N Engl J Med.1992;327:1135-1140.
Blumenthal D, Campbell EG, Anderson MS.
et al. Withholding research results in academic life science: evidence from
a national survey of faculty. JAMA.1997;277:1224-1228.
Campbell EG, Weissman JS, Causino N, Blumenthal D. Data withholding in academic medicine: characteristics of faculty denied
access to research results and biomaterials. Res Policy.2000;29:303-312.
Campbell EG, Clarridge BR, Gokhale NN.
et al. Data withholding in academic genetics: evidence from a national survey. JAMA.2002;287:473-480.
Rabino I. Societal and commercial issues affecting the future of biotechnology
in the United States: a survey of researchers' perceptions. Naturwissenschaften.1998;85:109-116.
McCrary SV, Anderson CB, Jakovljevic J.
et al. A national survey of policies on disclosure of conflicts of interest
in biomedical research. N Engl J Med.2000;343:1621-1626.
Cho MK, Shohara R, Schissel A, Ressie D. Policies on faculty conflicts of interest at US universities. JAMA.2000;284:2203-2208.
Lo B, Wolf LE, Berkely A. Conflict-of-interest policies for investigators in clinical trials. N Engl J Med.2000;343:1616-1620.
Krimsky S, Rothenberg L. Conflict of interest policies in science and medical journals: editorial
practices and author disclosures. Sci Eng Ethics.2001;7:205-218.
Dorman PJ, Counsell C, Sandercock P. Reports of randomized trials in acute stroke, 1955 to 1995: what proportions
were commercially sponsored? Stroke.1999;30:1995-1998.
Hussain A, Smith R. Declaring financial competing interests: survey of five general medical
Schulman K, Seils D, Timbie J.
et al. A national survey of provisions in clinical-trial agreements between
medical schools and industry sponsors. N Engl J Med.2002;347:1335-1341.
Bero LA, Rennie D. Influences on the quality of published drug studies. Int J Technol Assess Health Care.1996;12:209-237.
Rothman K, Michels K. The continuing unethical use of placebo controls. N Engl J Med.1994;331:394-398.
Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation
of new treatments. Ann Intern Med.2000;133:455-463.
Not Available. Adequate and Well-controlled Studies, 21 CFR §314.126 (2001).
Not Available. Guidance for Industry: Choice of Control Group and Related Issues
in Clinical Trials. Washington, DC: Food and Drug Administration; 2001.
Edwards SJ, Lilford RJ, Braunholtz DA.
et al. Ethical issues in the design and conduct of randomized controlled trials. Health Technol Assess.1998;2:i-vi, 1-132.
Rennie D. Fair conduct and fair reporting of clinical trials. JAMA.1999;282:1766-1768.
Berk PD, Sacks HS. Assessing the quality of randomized controlled trials: quality of design
is not the only relevant variable. Hepatology.1999;30:1332-1334.
Jadad AR, Moore RA, Carroll D.
et al. Assessing the quality of reports of randomized clinical trials: is
blinding necessary. Control Clin Trials.1996;17:1-12.
Emanuel E, Steiner D. Institutional conflict of interest. N Engl J Med.1995;332:262-267.
Blumenthal D. Growing pains for new academic/industry relationships [see comments]. Health Aff (Millwood).1994;13:176-193.
Gelijns A, Thier S. Medical innovation and institutional interdependence: rethinking university-industry
American Society of Gene Therapy. Policy of the American Society of Gene Therapy on financial conflict
of interest in clinical research [adopted April 5, 2000]. Available at: http://www.asgt.org/policy/index.html. Accessed
June 5, 2002.
Healy B, Campeau L, Gray R.
et al. Conflict of interest guidelines for a multicenter clinical trial of
treatment after coronary-artery bypass-graft surgery. N Engl J Med.1989;320:949-951.
Topol E, Armstrong P, Werf FV.
et al. Confronting the issues of patient safety and investigator conflict
of interest in an international clinical trial of myocardial reperfusion. J Am Coll Cardiol.1992;19:1123-1128.
Not Available. Report on Individual and Institutional Financial Conflict of
Interest . Washington, DC: American Association of Universities; 2001.
Coyle S. Physician-industry relations, Part 1: individual physicians. Ann Intern Med.2002;136:396-402.
Coyle S. Physician-industry relations, Part 2: organizational issues. Ann Intern Med.2002;136:403-406.
Morin K, Rakatansky H, Riddick F.
et al. Managing conflicts of interest in the conduct of clinical trials. JAMA.2002;287:78-84.
Task Force on Financial Conflicts of Interest in Clinical Research. Protecting Subjects, Preserving Trust, Promoting
Progress II: Principles and Recommendations for Oversight of an Institution's
Financial Interests in Human Subjects Research. Washington, DC: Association of American Medical Colleges; 2002.
DeAngelis C, Fontanarosa P, Flanagin A. Reporting financial conflicts of interest and relationships between
investigators and research sponsors. JAMA.2001;286:89-91.
Davidoff F, DeAngelis C, Drazen J.
et al. Sponsorship, authorship, and accountability. JAMA.2001;286:1232-1234.
Rettig RA. The industrialization of clinical research. Health Aff (Millwood).2000;19:129-146.
Press E, Washburn J. The kept university. Atlantic Monthly.March 2000:39-54.
Kassirer J. Pseudoaccountability. Ann Intern Med.2001;134:587-590.
Horton R, Smith R. Time to register randomised trials. Lancet.1999;354:1138-1139.
McCray AT. Better access to information about clinical trials. Ann Intern Med.2000;133:609-614.